Literature DB >> 19878056

Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura.

Jose Antonio Pérez-Simón1, Soraya Tabera, María Eugenia Sarasquete, María Díez-Campelo, Javier Canchado, Luis Ignacio Sánchez-Abarca, Belén Blanco, Ignacio Alberca, Carmen Herrero-Sánchez, Consuelo Cañizo, Jesús F San Miguel.   

Abstract

BACKGROUND AIMS: Immune thrombocytopenic purpura (ITP) is a bleeding disorder characterized by an accelerated destruction of platelets as a result of the presence of autoreactive antibodies. Patients with ITP also display activated platelet-autoreactive T cells. Mesenchymal stem cells (MSC) inhibit both T- and B-cell activation and may have functional impairments in autoimmune disorders.
METHODS: We analyzed the potential role of MSC in the pathogenesis of ITP.
RESULTS: MSC from ITP showed an impaired proliferative capacity and a lower capability of inhibiting activated T-cell proliferation compared with healthy donors. While MSC from controls showed a decreased expression of p27 after stimulation with platelet-derived growth factor, this effect was not observed in MSC from patients. Furthermore, MSC from healthy donors down-regulated p16 upon exposure to platelet-released supernatant, while this effect was not observed for ITP. Interestingly, caspase 9 expression was higher in MSC from ITP.
CONCLUSIONS: These abnormalities suggest a role of MSC malfunction in the physiopathology of the disease and may have therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19878056     DOI: 10.3109/14653240903051558

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  21 in total

1.  Vitamin D analog EB1089 could repair the defective bone marrow-derived mesenchymal stromal cells in patients with systemic lupus erythematosus.

Authors:  Jing-Jing Xu; Yan-Bin Sun; Xiao-Li Zhang; Xiao-Fei Wang
Journal:  Int J Clin Exp Med       Date:  2015-01-15

2.  Platelet-Derived Growth Factor-BB Protects Mesenchymal Stem Cells (MSCs) Derived From Immune Thrombocytopenia Patients Against Apoptosis and Senescence and Maintains MSC-Mediated Immunosuppression.

Authors:  Jia-Min Zhang; Fei-Er Feng; Qian-Ming Wang; Xiao-Lu Zhu; Hai-Xia Fu; Lan-Ping Xu; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Hui Zhang
Journal:  Stem Cells Transl Med       Date:  2016-07-28       Impact factor: 6.940

3.  Integrated mRNA and miRNA profiling revealed deregulation of cellular stress response in bone marrow mesenchymal stem cells derived from patients with immune thrombocytopenia.

Authors:  Jia-Min Zhang; Xiao-Lu Zhu; Jing Xue; Xiao Liu; X Long Zheng; Ying-Jun Chang; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Hui Zhang
Journal:  Funct Integr Genomics       Date:  2018-02-13       Impact factor: 3.410

4.  Favorable response of chronic refractory immune thrombocytopenic purpura to mesenchymal stem cells.

Authors:  Baijun Fang; Ling Mai; Ning Li; Yongping Song
Journal:  Stem Cells Dev       Date:  2011-08-12       Impact factor: 3.272

5.  Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial.

Authors:  Jose A Pérez-Simon; Olga López-Villar; Enrique J Andreu; José Rifón; Sandra Muntion; María Diez Campelo; Fermín M Sánchez-Guijo; Carmen Martinez; David Valcarcel; Consuelo Del Cañizo
Journal:  Haematologica       Date:  2011-03-10       Impact factor: 9.941

Review 6.  Interferon-gamma modification of mesenchymal stem cells: implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation.

Authors:  Kisha Nandini Sivanathan; Stan Gronthos; Darling Rojas-Canales; Benjamin Thierry; P Toby Coates
Journal:  Stem Cell Rev Rep       Date:  2014-06       Impact factor: 5.739

Review 7.  Bottlenecks in the Efficient Use of Advanced Therapy Medicinal Products Based on Mesenchymal Stromal Cells.

Authors:  Natalia Escacena; Elena Quesada-Hernández; Vivian Capilla-Gonzalez; Bernat Soria; Abdelkrim Hmadcha
Journal:  Stem Cells Int       Date:  2015-07-27       Impact factor: 5.443

8.  Multipotent mesenchymal stromal cells from patients with newly diagnosed type 1 diabetes mellitus exhibit preserved in vitro and in vivo immunomodulatory properties.

Authors:  Juliana Navarro Ueda Yaochite; Kalil Willian Alves de Lima; Carolina Caliari-Oliveira; Patricia Vianna Bonini Palma; Carlos Eduardo Barra Couri; Belinda Pinto Simões; Dimas Tadeu Covas; Júlio César Voltarelli; Maria Carolina Oliveira; Eduardo Antônio Donadi; Kelen Cristina Ribeiro Malmegrim
Journal:  Stem Cell Res Ther       Date:  2016-01-18       Impact factor: 6.832

Review 9.  The uncertain role of unmodified mesenchymal stem cells in tumor progression: what master switch?

Authors:  Liyang Zhang; Juanjuan Xiang; Guiyuan Li
Journal:  Stem Cell Res Ther       Date:  2013-03-18       Impact factor: 6.832

10.  Human Allogeneic Bone Marrow and Adipose Tissue Derived Mesenchymal Stromal Cells Induce CD8+ Cytotoxic T Cell Reactivity.

Authors:  Marieke Roemeling-van Rhijn; Marlies E Reinders; Marcella Franquesa; Anja U Engela; Sander S Korevaar; Helene Roelofs; Paul G Genever; Jan Nm Ijzermans; Michiel Gh Betjes; Carla C Baan; Willem Weimar; Martin J Hoogduijn
Journal:  J Stem Cell Res Ther       Date:  2013-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.